General MedicationsSUBCUTANEOUSStandard

YORVIPATH

PALOPEGTERIPARATIDE

Standard Dose

EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)

Max Dose

Refer to approved labeling

Primary Use

Review priority: N/A Marketing status: Prescription

Summary

Approval overview YORVIPATH is listed in Drugs@FDA under application 216490 (NDA).

Review priority: N/A Marketing status: Prescription Active ingredient PALOPEGTERIPARATIDE Form and strength SOLUTION;SUBCUTANEOUS - EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) Sponsor ASCENDIS PHARMA BONE Submission history Latest submission status date: 2025-10-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview YORVIPATH is listed in Drugs@FDA under application 216490 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient PALOPEGTERIPARATIDE Form and strength SOLUTION;SUBCUTANEOUS - EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) Sponsor ASCENDIS PHARMA BONE Submission history Latest submission status date: 2025-10-16 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: N/A

Interaction Notes

No interaction notes stored yet.